The medication group experienced a BMI drop of 16%, while the control group saw just a 0.6% reduction
In these conditions, the body cant effectively convert fat into energy due to inadequate carnitine levels
Novos next-generation answer, CagriSema, trailed Zepbound in a head-to-head trial that missed its primary endpoint, leaving the Danish firm to consolidate around semaglutide after cutting roughly 9,000 jobs and warning of a weaker 2026
However, caution is advised for patients with specific thyroid-related conditions
Clinical trials found hair shedding in up to 5.7% of participants, and the MHRA has formally classified hair loss as a common side effect, affecting up to 1 in 10 users
This is where the SeekPeptides reconstitution calculator extends the charts